|
|
|
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Amended Notice
Changes in the Agenda portion of the meeting.
| Center | Date | Time | Location |
|---|---|---|---|
| CDER | November 18, 2003 November 19, 2003 |
8 a.m. - 5 p.m. 8 a.m. - 12 noon |
Holiday Inn |
Notice:
The Food and Drug Administration (FDA) is announcing an amendment to the notice
of meeting of the Anesthetic and Life Support Drugs Advisory Committee. This
meeting was announced in the FEDERAL REGISTER of October 8, 2003 (68 FR 58115).
The amendment is being made to reflect a change in the agenda portion of the
document. There are no other changes.
Supplementary Information:
In the Federal Register of October 8, 2003, FDA announced
that a meeting of the Anesthetic and Life Support Drugs Advisory Committee would
be held on November 18, and 19, 2003. On pages 58115-58116, the agenda portion
of the meeting is amended to read as follows:
Agenda: On November 18, 2003, the committee will discuss the
evaluation and communication of risk related to QTc prolongation by Droperidol
(inapsine) Akorn, Inc.
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate committee link).
Contact Person:
Johanna Clifford, Center for Drug Evaluation and Research, HFD-21, Food and
Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or by express delivery
to: 5630 Fishers Lane, Room 1093, Rockville MD 20857, (301) 827-7001, or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington,
DC area), code 12529. Please call the Information Line for up-to-date information
on this meeting.
[Full Original FR Notice] [Amendment to Original FR Notice]